Long-Term Business GSK to Invest 30 Billion Dollars in USA for R&D, Supply Chain Infrastructure

Related Vendors

GlaxoSmithKline

Glatt Ingenieurtechnik GmbH

Donadon SDD Srl

ProMinent GmbH

GSK’s mega investment includes a new 1.2-billion-dollar investment in advanced manufacturing facilities and AI and advanced digital technologies. With this, the company aims to develop new, next-generation biopharma factories and laboratories in the USA.

London/UK – GSK has recently announced plans to invest 30 billion dollars across the United States in research and development and supply chain infrastructure over the next five years.

This includes a new 1.2-billion-dollar investment in advanced manufacturing facilities and AI and advanced digital technologies, to deliver new, next-generation biopharma factories and laboratories in the United States. These investments build on GSK’s strong innovation and manufacturing footprint and capabilities in the United States today, developing and making products in the United States for the United States.

The 1.2-billion-dollar investment includes:

• Construction of an additional new biologics flex factory at Upper Merion, Pennsylvania to deliver potential best-in-class new medicines for respiratory disease (COPD, asthma) and cancer (haematological, gynaecological, lung and other solid tumours). Construction is planned to commence in 2026

• New AI and advanced digital technology capabilities across GSK’s existing 5 manufacturing sites in 4 States (Pennsylvania, North Carolina, Maryland, and Montana)

• New drug substance manufacturing capabilities

• New and enhanced device and auto-injector capabilities and assembly

Commenting on the State Visit and the announcement, GSK CEO Emma Walmsley said: “Alongside the many longstanding and vital shared interests that connect the U.K. and the United States, is advancing life sciences to get ahead of disease. The State Visit brings together two countries that have led the world in science and healthcare innovation. We are proud to be part of both. Here in the U.K., we continue to invest in a significant manufacturing base and more than 1.5 billion pounds in R&D every year. Today, we are committing to invest at least 30 billion dollars in the United States over the next 5 years, further bolstering the already strong R&D and supply chain we have in the country. 1.2 billion dollars of the announcement includes construction of an additional next-gen biologics “flex” factory, powered by AI, advanced technologies and expert talent to produce transformational new respiratory and cancer medicines for American patients.”

The 30-billion-dollar investment in the U.S. includes capital investments across GSK’s U.S. supply chain, as well as increased investment in R&D drug discovery and development and clinical trial activity, with the U.S. expected to rank first globally for the number of studies, sites and clinical trials participants conducted by GSK over the next five years.

The recent announcement means GSK has committed new investments of approximately 2 billion dollars in U.S. manufacturing over the last 12 months. In October 2024, construction began of a new 800-million-dollar facility at GSK’s Marietta, Pennsylvania site, doubling the size and capacity of the site. These new manufacturing investments will create hundreds of highly skilled jobs (in addition to construction jobs), building upon GSK’s approximately 15,000 strong U.S. workforce.

(ID:50566416)